NYSEAMERICAN:ATNM - Actinium Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $31.67
  • Forecasted Upside: 558.35 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$4.81
▼ -0.16 (-3.22%)

This chart shows the closing price for ATNM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Actinium Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATNM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATNM

Analyst Price Target is $31.67
▲ +558.35% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Actinium Pharmaceuticals in the last 3 months. The average price target is $31.67, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 558.35% upside from the last price of $4.81.

This chart shows the closing price for ATNM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Actinium Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/6/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/12/2022HC WainwrightReiterated RatingBuy$45.00
10/6/2021Maxim GroupReiterated RatingBuy$25.00
9/15/2021Alliance Global PartnersBoost Price TargetBuy$20.00 ➝ $25.00
8/3/2021HC WainwrightLower Price TargetBuy$57.00 ➝ $45.00
4/1/2021HC WainwrightLower Price TargetBuy$65.00 ➝ $57.00
3/10/2021HC WainwrightReiterated RatingBuy$65.00
12/31/2020William BlairReiterated RatingBuy
12/7/2020HC WainwrightReiterated RatingBuy$65.00
12/4/2020William BlairReiterated RatingBuy
11/5/2020Alliance Global PartnersInitiated CoverageBuy$25.00
8/21/2020Maxim GroupReiterated RatingBuy
6/4/2020HC WainwrightReiterated RatingBuy
6/4/2020HC WainwrightInitiated CoverageBuy$90.00
4/17/2020Maxim GroupInitiated CoverageBuy$45.00
12/11/2019Maxim GroupReiterated RatingBuy$45.00
10/25/2019Maxim GroupReiterated RatingBuy$45.00
8/8/2019William BlairReiterated RatingOutperform
8/8/2019William BlairInitiated CoverageOutperform
6/4/2019Maxim GroupSet Price TargetBuy$90.00
3/20/2019Maxim GroupReiterated RatingBuy$90.00
2/26/2019OppenheimerSet Price TargetBuy$150.00
2/5/2019Maxim GroupSet Price TargetBuy$90.00
12/4/2018Roth CapitalSet Price TargetBuy$180.00
12/3/2018Maxim GroupSet Price TargetBuy$90.00
11/28/2018OppenheimerSet Price TargetBuy$150.00
11/8/2018Roth CapitalSet Price TargetBuy$180.00
10/10/2018Roth CapitalSet Price TargetBuy$180.00
8/15/2018B. RileySet Price TargetBuy$90.00
8/14/2018Maxim GroupReiterated RatingBuy$90.00
7/12/2018B. RileyBoost Price TargetBuy ➝ Buy$82.50 ➝ $90.00
6/14/2018Maxim GroupReiterated RatingBuy
5/23/2018B. RileySet Price TargetBuy$90.00
3/28/2018Maxim GroupSet Price TargetBuy$90.00
3/20/2018Maxim GroupSet Price TargetBuy$90.00
3/14/2018B. RileySet Price TargetBuy$90.00
2/16/2018B. RileySet Price TargetBuy$90.00
12/27/2017B. RileySet Price TargetBuy$90.00
12/27/2017Maxim GroupSet Price TargetBuy$90.00
12/12/2017Maxim GroupSet Price TargetBuy$90.00
12/12/2017B. RileySet Price TargetBuy$90.00
12/6/2017B. RileyInitiated CoverageBuy ➝ Buy$82.50
12/6/2017Maxim GroupSet Price TargetBuy$90.00
11/30/2017Maxim GroupSet Price TargetBuy$90.00
11/14/2017Maxim GroupSet Price TargetBuy$90.00
11/1/2017Maxim GroupSet Price TargetBuy$90.00
10/25/2017Maxim GroupReiterated RatingBuy$90.00
10/23/2017HC WainwrightReiterated RatingBuy$180.00
10/23/2017Roth CapitalReiterated RatingBuy$180.00
10/5/2017Maxim GroupReiterated RatingBuy$90.00
9/14/2017Maxim GroupInitiated CoverageBuy$90.00
(Data available from 6/30/2017 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/2/2021
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/1/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/31/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/2/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/1/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/1/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Actinium Pharmaceuticals logo
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.
Read More

Today's Range

Now: $4.81
Low: $4.80
High: $5.02

50 Day Range

MA: N/A

52 Week Range

Now: $4.81
Low: $4.41
High: $10.30

Volume

122,498 shs

Average Volume

506,736 shs

Market Capitalization

$114.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.48

Frequently Asked Questions

What sell-side analysts currently cover shares of Actinium Pharmaceuticals?

The following Wall Street sell-side analysts have issued reports on Actinium Pharmaceuticals in the last year: Alliance Global Partners, HC Wainwright, and Maxim Group.
View the latest analyst ratings for ATNM.

What is the current price target for Actinium Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Actinium Pharmaceuticals in the last year. Their average twelve-month price target is $31.67, suggesting a possible upside of 558.4%.
View the latest price targets for ATNM.

What is the current consensus analyst rating for Actinium Pharmaceuticals?

Actinium Pharmaceuticals currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ATNM will outperform the market and that investors should add to their positions of Actinium Pharmaceuticals.
View the latest ratings for ATNM.

How do I contact Actinium Pharmaceuticals' investor relations team?

Actinium Pharmaceuticals' physical mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The biotechnology company's listed phone number is (646) 677-3870 and its investor relations email address is [email protected] The official website for Actinium Pharmaceuticals is www.actiniumpharmaceuticals.com. Learn More about contacing Actinium Pharmaceuticals investor relations.